Smoking and schizophrenia

Joseph P. McEvoy, John Lindgren

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Patients with schizophrenia smoke at a higher prevalence rate (80%) than the general population (30%). Those patients with schizophrenia who smoke have an earlier age of onset and may have more refractory psychopathology. Smoking improves sensory gating, sustained attention, and cognitive performance in patients with schizophrenia. Conventional antipsychotic drugs initially increase smoking. Switching to the atypical antipsychotic, clozapine, decreases smoking. Smoking decreases the bioavailability of many antipsychotic drugs.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalDrug Development Research
Issue number3-4
StatePublished - 1996
Externally publishedYes


  • Antipsychotic drugs
  • Nicotine
  • Schizophrenia
  • Smoking

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'Smoking and schizophrenia'. Together they form a unique fingerprint.

Cite this